AFT Pharmaceuticals’ completes first deal in South America

Market and Media release 20 June 2019


AFT Pharmaceuticals’ completes first deal in South America
AFT signs Maxigesic
®
Licensing Agreement with Barcelona-based Galenicum Vitae S.L.U for
Colombia, Peru and Chile
.


AFT Pharmaceuticals today announces it has established a beachhead in
South America after signing a licensing agreement with Galenicum Vitae.

Galenicum is a Barcelona-based pharmaceutical company with offices across
South America and around the globe. It plans to market, sell and distribute
AFT’s patented combination analgesic, Maxigesic
®
, in Colombia, Peru and
Chile. Products covered by the new agreement include tablets and oral liquid
for paediatric use.

AFT Managing Director, Dr Hartley Atkinson, says: “We are pleased to be
making progress on licensing agreements in Latin America. These agreements
will be a welcome addition to the Central American markets already licensed,
with sales now underway - or due to start – in the current financial year in El
Salvador, Guatemala, Honduras, Costa Rica and Nicaragua.”

Dr Atkinson said AFT expects registration approvals in the territories covered by
the Galenicum agreement to occur prior to the end of 2021 with sales
occurring in the following year.

Galenicum Vitae’s CEO, Sergio Malagrida, said: “For us, including a product
such us Maxigesic® in our portfolio represents a great opportunity to provide
an innovative product reinforcing our market offering. We believe that this will
be the initial launch of a future greater line of products”.

Peru, Colombia and Chile have a combined population of almost 100 million
people and the combined retail current value of the over-the-counter pain
relief market is NZ$749 million
1
.

Maxigesic
®
is a patented, fixed ratio of ibuprofen for anti-inflammation
management and paracetamol (also called acetaminophen) for pain
management.

For more information:


Investors Media
Dr Hartley Atkinson Richard Inder
CEO, AFT Pharmaceuticals Ltd The Project
Phone: +64 9 488 0232 Phone: 021 645 643
Email: richard@theproject.co.nz




About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops,
markets and distributes a broad portfolio of pharmaceutical products across a
wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over-the-counter (OTC), prescription
and hospital. Our product portfolio comprises both proprietary and in-licensed
products, and includes patented, branded and generic drugs. Our business
model is to develop and in-license products for sale by our own dedicated
sales teams in our home markets of Australia and New Zealand and in certain
Southeast Asian markets, and to out-license our products to local licensees
and distributors to the rest of the world. For more information:
https://www.aftpharm.com/




About Galenicum Vitae S.L.U
Believe in life

High quality affordable pharmaceuticals delivered worldwide

Galenicum was founded in Barcelona in 2003 by three young visionaries who
wanted to bring quality and affordable Active Principle Ingredients to the
Spanish Pharmaceutical industry, emerging on generics at that time. Since
then, the company has grown significantly to become a global ecosystem of
five different businesses within the Pharma and Food supplements space.

1
Euromonitor, 2018.

Today, Galenicum covers the full pharmaceutical value chain,
including Trading of Active Principle Ingredients (API), Research and
Development of Finished Dosage Forms (FDFs), Intellectual Property (IP) and
Patent litigation, Regulatory Affairs, Clinical trials, Manufacturing facilities,
Quality Assurance, Supply Chain and Commercialization.

Galenicum holds business-to-business partnerships with other pharmaceutical
and food companies in over 40 countries - and counting- under
the Galenicum Axium and Galenicum Food brands respectively. Galenicum
also delivers business-to-consumer dermatological products in Spain under
the Galenicum Derma brand, and a broad spectrum of pharmaceuticals in
most therapeutical areas in Latin America and Asia under the Galenicum
Vitae brand.

Galenicum keeps its original purpose to improve quality and affordability of
medicine: A non-stop challenge, An inspiration for more. From Barcelona to
the world.